Advertisement
APUS vs DERM
Which Stock Would AI Choose? Apimeds Pharmaceuticals US (APUS) vs. Journey Medical (DERM) Stock Comparison
Key Takeaways
- APUS is an early-stage company that has recently pivoted toward digital-asset (bitcoin treasury) operations, while DERM is a commercial-stage dermatology pharmaceutical company with marketed, revenue-generating products.
- DERM generates recurring revenue from eight branded, FDA (U.S. Food and Drug Administration)-approved drugs; APUS reported no biopharmaceutical revenue and disclosed a going-concern risk in its most recent annual filing.
- Sector exposure is sharply different: APUS blends biotechnology with bitcoin and blockchain assets, whereas DERM is concentrated in specialty dermatology healthcare.
- APUS carries elevated financial risk from its thin cash position and recent merger; DERM's risk profile centers on product competition and commercialization execution.
- Relative performance and sentiment are likely driven by broader bitcoin and digital-asset trends for APUS versus specialty-pharma fundamentals for DERM.
Introduction
Investors comparing APUS and DERM are essentially weighing two very different risk profiles within the small-cap universe. One is an emerging digital-asset and biotechnology venture, while the other is a commercial-stage pharmaceutical company with established revenue. This stock comparison is most relevant to traders and investors assessing market positioning, growth catalysts, and relative performance across contrasting industries. Understanding how each company's business model, financial health, and recent momentum interact can help clarify which name may better align with a given risk tolerance or portfolio objective.
APUS Overview and Recent Performance
Apimeds Pharmaceuticals US, Inc. (APUS), listed on NYSE American, has transitioned toward providing digital-asset treasury solutions focused on bitcoin treasury infrastructure. Following a merger completed in late 2025, the company now operates across two segments: a biopharmaceutical arm advancing a clinical-stage candidate and a digital-asset operations arm tied to blockchain holdings. APUS is a subsidiary of South Korea-based Inscobee, Inc.
Recent market activity has reflected the company's early-stage, pre-revenue profile. In its latest annual filing, APUS reported no biopharmaceutical revenue and disclosed a net loss, a limited cash position, and a going-concern warning. These factors, combined with its exposure to the volatility of bitcoin and related digital assets, have shaped sentiment. As a result, APUS's stock behavior is more closely linked to cryptocurrency market swings and restructuring milestones than to traditional operational fundamentals.
DERM Overview and Recent Performance
Journey Medical Corporation (DERM) is a commercial-stage pharmaceutical company based in Scottsdale, Arizona, focused on developing and marketing FDA-approved prescription treatments for dermatological conditions. The company currently markets eight branded products and was founded by Fortress Biotech, Inc.
DERM reported its full-year 2025 financial results and recent corporate highlights, followed by first-quarter 2026 results, underscoring a steady cadence of operational disclosures. Recent weeks have been shaped by the company's commercialization progress, product portfolio execution, and participation in healthcare investor conferences. Unlike APUS, DERM has a tangible revenue base and a sales-and-marketing infrastructure, which tends to produce more fundamentally driven price behavior. Its sentiment is influenced by prescription trends, competitive dynamics in dermatology, and the pace of any pipeline or business-development activity.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, statistics, and set of covered tickers. Because not every bot fits every market regime, Tickeron curates a dedicated Trending AI Robots section to highlight only the bots best suited to current market conditions. This selective approach helps traders filter through a large, diverse bot universe to find strategies that are performing well right now. Whether you are comparing names like APUS and DERM or scanning broader opportunities, exploring the Trending AI Robots page can be a practical way to see which automated strategies are currently in favor.
Head-to-Head Comparison
Across key dimensions, these two companies represent opposing investment theses. In terms of business model, DERM is a revenue-generating specialty pharmaceutical company, while APUS is a pre-revenue entity repositioning around bitcoin treasury infrastructure. Their growth drivers also differ: DERM relies on prescription volume, product expansion, and potential licensing deals, whereas APUS depends on digital-asset appreciation, blockchain adoption, and the future progress of a clinical-stage candidate.
On recent momentum, APUS is more sensitive to cryptocurrency sentiment, which can swing sharply in either direction, while DERM's moves are more anchored to earnings and commercialization news. Risk factors are equally distinct. APUS faces liquidity constraints and a disclosed going-concern risk, whereas DERM faces competitive and market-access risks common to specialty pharma but benefits from an established revenue stream. These contrasts make the pair a useful illustration of how market positioning and sector exposure can diverge even among smaller-cap stocks.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and the presence of durable catalysts, Tickeron's AI would likely favor DERM in the current environment. DERM's recurring revenue, established product portfolio, and more fundamentally driven price action tend to produce steadier, more identifiable trends than APUS's reliance on early-stage restructuring and volatile digital-asset exposure. APUS's exposure to bitcoin could offer substantial upside under favorable market conditions, but its thin cash position and going-concern disclosure introduce elevated uncertainty. Accordingly, an AI-driven assessment would lean toward DERM on a relative basis, while acknowledging that APUS remains a higher-risk, higher-uncertainty profile that may appeal to a different segment of traders.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APUS is a Buy and DERM is a Buy.
DERM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 48 | |
P/E GROWTH RATING 1..100 | 33 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| APUS | DERM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| Advances ODDS (%) | 8 days ago 90% | 3 days ago 86% |
| Declines ODDS (%) | 2 days ago 90% | 8 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APUS’s FA Score shows that 1 FA rating(s) are green while DERM’s FA Score has 1 green FA rating(s).
- APUS’s FA Score: 1 green, 4 red.
- DERM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APUS’s TA Score shows that 5 TA indicator(s) are bullish while DERM’s TA Score has 5 bullish TA indicator(s).
- APUS’s TA Score: 5 bullish, 5 bearish.
- DERM’s TA Score: 5 bullish, 6 bearish.
Price Growth
APUS (@Pharmaceuticals: Generic) experienced а -55.59% price change this week, while DERM (@Pharmaceuticals: Generic) price change was +7.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.61%. For the same industry, the average monthly price growth was -8.00%, and the average quarterly price growth was +30.03%.
Reported Earning Dates
DERM is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-4.61% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
APUS and
Correlation & Price change
A.I.dvisor indicates that over the last year, APUS has been loosely correlated with DERM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if APUS jumps, then DERM could also see price increases.
| Ticker / NAME | Correlation To APUS | 1D Price Change % | ||
|---|---|---|---|---|
| APUS | 100% | -18.00% | ||
| DERM - APUS | 49% Loosely correlated | -1.75% | ||
| SNOA - APUS | 41% Loosely correlated | -2.34% | ||
| ACB - APUS | 24% Poorly correlated | N/A | ||
| PAHC - APUS | 21% Poorly correlated | +0.36% | ||
| TRLV - APUS | 11% Poorly correlated | -0.28% | ||
More | ||||
DERM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DERM has been loosely correlated with APUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DERM jumps, then APUS could also see price increases.
| Ticker / NAME | Correlation To DERM | 1D Price Change % | ||
|---|---|---|---|---|
| DERM | 100% | -1.75% | ||
| APUS - DERM | 49% Loosely correlated | -18.00% | ||
| CHRS - DERM | 27% Poorly correlated | -4.13% | ||
| CRDL - DERM | 23% Poorly correlated | -6.02% | ||
| AMLX - DERM | 23% Poorly correlated | -3.51% | ||
| ETON - DERM | 23% Poorly correlated | +0.95% | ||
More | ||||